Drugs & Healthcare
Dermavir is a Dendritic Cell-Targeting Therapeutic Vaccine Technology Platform.
Therapeutic Vaccine for treatment of HIV, referred to as “DermaVir”, is effective in boosting immune response which kills HIV-infected cells. Human clinical trials have demonstrated vaccine is capable of killing HIV-infected cells. DermaVir has a safety profile similar to vaccines used in healthy adults and children. DermaVir can also be a co-treatment option if administered with antiretroviral therapy.
|Pre-sale start date||30 Mar 2018|
|Pre-sale end date||15 May 2018|
|Pre-sale token supply||9,000,000|
|ICO start date||15 May 2018|
|ICO end date||30 May 2018|
|ICO token supply||1,000,000|
|Additional Token Emission||No|
Presale 1st stage - 30% discount
66% - ICO
3% - Bounty
21% - future sell
15% - FDA Documentation
Type of scores
Rating Review and Analytics
|Start ICO||15 May 2018|
|End ICO||30 May 2018|
|Price||1 GIC = 1 USD|
Click vote if you want this project to be Post-ICO Rated.
The vote has been noted.